Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function
Abstract
Background: In primary percutaneous coronary intervention (PCI), glycoprotein (GP) IIb/IIIa inhibitors are often given in order to attain and maintain better myocardial perfusion. Wetested the hypothesis that intracoronary (IC) bolus of GP IIb/IIIa inhibitors might producea greater improvement in left ventricular (LV) systolic and diastolic function than an intravenous(IV) bolus.
Methods and results: Seventy seven patients undergoing primary PCI for their firstST elevation myocardial infarction (STEMI) were randomly assigned to either an IC or IVbolus of GP IIb/IIIa inhibitor, followed by IV infusion. Compared with the echocardiographic findings within 3 days after PCI, LV ejection fraction was higher at 1 year, with no significant differences between the IV and IC groups (IV: 44% vs. 49%, p = 0.001; IC: 43% vs. 48%,p < 0.001). LV diastolic function (E/E’) did not significantly change at 1 year by either approach.
Conclusions: LV systolic function improved by a similar magnitude following primary PCI, with either IC or IV bolus administration of GP IIb/IIIa inhibitor therapy. However, no significant changes were observed in LV diastolic function.
Keywords: ST elevation myocardial infarctionprimary percutaneous coronary interventionintracoronary GP IIb/IIIa inhibitorsdiastolic function